Home » Newsletters » BioWorld Science

BioWorld Science

July 26, 2016

View Archived Issues

Chugai Pharmaceutical updates progress of second quarter 2016

Targeting Tat expression pathways may be useful for reactivation of latent HIV-1

Fetuin-B as plasma biomarker related to the severity of lung function in COPD

FDA's clinical hold on CGF-166 lifted

Topline 24-week data from phase IIb study of ALD-403 for persistent migraine prevention

FDA issues complete response letter for Ocular Therapeutix's Dextenza

Celsion reports further data from OVATION study in ovarian cancer

HHS patents TDP2 inhibitors

Valneva completes phase II study of C. difficile vaccine

Calibr discloses dimeric derivatives of amiloride

Warp Drive Bio describes CEP250 modulators

Tobira's cenicriviroc improves liver fibrosis in phase IIb study in NASH

Advinus Therapeutics presents retinoid RORgammaT antagonists

FDA grants new breakthrough therapy designation to Darzalex in multiple myeloma

Opthea reports data from ongoing first-in-human trial of OPT-302 for wet AMD

ROCK2 signaling induces a subset of TFH cells through opposing effects on STATs

Novel bispecific immunoadhesin shows promise for HIV prevention and immunotherapy

Exosome-mediated macrophage reprogramming as promising strategy for pancreatic cancer therapy

AbbVie and BMS to evaluate Rova-T with checkpoint inhibitors for SCLC

Newron plans Xadago NDA resubmission

FDA approves AbbVie's Viekira XR

FDA accepts Calithera Biosciences' IND for CB-1158

Ebola Zaire vaccine wins FDA breakthrough therapy designation and PRIME status

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...